D
Dae Won Kim
Researcher at Sungkyunkwan University
Publications - 5
Citations - 182
Dae Won Kim is an academic researcher from Sungkyunkwan University. The author has contributed to research in topics: Chemotherapy & Autologous stem-cell transplantation. The author has an hindex of 3, co-authored 5 publications receiving 172 citations.
Papers
More filters
Journal ArticleDOI
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.
Won Ki Kang,Chaehwa Park,Hyunah Lee Yoon,Won Seog Kim,Sung-Soo Yoon,Mark Hong Lee,Keunchil Park,Ki-Hyun Kim,Hyun Jeong,Jeong-A Kim,Jeong-A Kim,Seok Jin Nam,Jung-Hyun Yang,Young-Ik Son,Chung-Hwan Baek,Jung Ho Han,Howe J. Ree,Eil Soo Lee,Sun-Hee Kim,Dae Won Kim,Yong Chan Ahn,Seung Jae Huh,Yeon Hyeon Choe,Je-Ho Lee,Mary H. Park,Gyoung-Sun Kong,Eun Young Park,Yoon-Koo Kang,Yung-Jue Bang,Nam-Sun Paik,Soon Nam Lee,Seon Hee Kim,Sun-Young Kim,Paul D. Robbins,Hideaki Tahara,Michael T. Lotze,Chan H. Park +36 more
TL;DR: Gene therapy by peritumoral injection of IL-12-producing autologous fibroblasts is feasible, and promising in patients with advanced cancer, and there appears to be perturbation of systemic immunity.
Journal ArticleDOI
Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation
Moon Ki Choi,Eun Suk Kang,Dae Won Kim,Yonug Hyeh Ko,Hyeri Seok,Jin Hong Park,Dae Hee Pyo,Do Hoon Lim,Seok Jin Kim,Won Seog Kim +9 more
TL;DR: It is suggested that the combination of ifosfamide, carboplatin, etoposide, and dexamethasone may represent a feasible salvage treatment option for relapsed or refractory PCNSL, and that high-dose chemotherapy containing thiotepa and busulfan followed by ASCT may be effective for patients with a favorable toxicity profile.
Journal ArticleDOI
Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation
TL;DR: TCD chemotherapy can be an effective and feasible induction regimen prior to ASCT for myeloma patients, and patients with a stringent complete response without transplantation-related mortality are included.